Hanson Group has introduced international biomedical technologies, dedicated to building a clinical-grade CGT CDMO full-process platform for China's pharmaceutical industrial park, focusing on the field of cell therapy. It provides one-stop services ranging from process development, IND application, IIT clinical trials, pilot testing to commercial production, covering mainstream cell therapy categories such as CAR-T/ARST/NK/TIL/IEG/iPS stem cells. The platform strictly complies with NMPA GMP, GCP, and FDA/EMA international standards, filling the gap in high-end cell therapy CDMO production capacity in Northeast China.

Group production line configuration: 20 independent B+A isolation production lines, each capable of concurrently processing different cell therapy projects without interference. Annual production capacity: 800-1000 batches, covering preclinical process development, Phase I/II/III clinical production, and commercial pilot-scale manufacturing. Service Capacity: Annually handles 40-60 IND applications and over 100 IIT clinical trials, meeting the needs of innovative pharmaceutical companies in Northeast China and nationwide.